Eidogen-Sertanty Enhances iProtein iPad App
Eidogen-Sertanty released a major update to iProtein. The iProtein iPad app has been enhanced with multitasking support, native molecular editing, retrieval of protein coordinates, and site-similarity searching.
SAN DIEGO, CA, January 13, 2011
Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today the release of a major update to iProtein. The iProtein iPad app has been enhanced with new functionality including Molecular Materials Informatics' very powerful molecular editor (Embedded MMDS). Users of iProtein can now benefit from iPad native molecular editing to rapidly draw and search protein bound ligands.Other enhancements to iProtein include multitasking support, retrieval of protein and model coordinates, retrieval of sites through ligand names, and site-similarity searching across co-complexes within the proteome. For more complex site-similarity searching, users require a subscription to Eidogen-Sertanty's Target Informatics Platform (TIP).
iProtein is among the suite of Eidogen-Sertanty's iPhone and iPad applications which include Mobile Reagents, iKinase, iKinasePro, iKinasePro for iOS4 (iPhone), and alternative medicine related apps iYoga108 and iYoga108 for the iPhone.
For more information, please contact:
Steve Muskal
760-651-2885
pr@eidogen-sertanty.com
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit http://www.eidogen-sertanty.com.